La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Marksans Pharma Gestion
Gestion contrôle des critères 1/4
We currently do not have sufficient information about the CEO.
Informations clés
Mark Saldanha
Directeur général
₹52.2m
Rémunération totale
| Pourcentage du salaire du PDG | 92.0% |
| Durée du mandat du directeur général | 8.8yrs |
| Propriété du PDG | 43.8% |
| Durée moyenne d'occupation des postes de direction | pas de données |
| Durée moyenne du mandat des membres du conseil d'administration | 6yrs |
Mises à jour récentes de la gestion
Recent updates
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Jul 28
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Jun 07Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
May 31Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Nov 17This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25
Sep 01Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
May 27Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 04Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching
Jan 20Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?
Jan 05
Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%
Dec 21What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?
Dec 06These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely
Nov 19Marksans Pharma Limited's (NSE:MARKSANS) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Nov 04If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late
Oct 20Is Marksans Pharma Limited's (NSE:MARKSANS) Shareholder Ownership Skewed Towards Insiders?
Oct 05If You Had Bought Marksans Pharma (NSE:MARKSANS) Shares A Year Ago You'd Have Earned273% Returns
Sep 20Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹3b |
| Mar 31 2024 | n/a | n/a | ₹3b |
| Dec 31 2023 | n/a | n/a | ₹3b |
| Sep 30 2023 | n/a | n/a | ₹3b |
| Jun 30 2023 | n/a | n/a | ₹3b |
| Mar 31 2023 | ₹52m | ₹48m | ₹3b |
| Dec 31 2022 | n/a | n/a | ₹2b |
| Sep 30 2022 | n/a | n/a | ₹2b |
| Jun 30 2022 | n/a | n/a | ₹2b |
| Mar 31 2022 | ₹38m | ₹35m | ₹2b |
| Dec 31 2021 | n/a | n/a | ₹2b |
| Sep 30 2021 | n/a | n/a | ₹2b |
| Jun 30 2021 | n/a | n/a | ₹3b |
| Mar 31 2021 | ₹10m | ₹10m | ₹2b |
| Dec 31 2020 | n/a | n/a | ₹2b |
| Sep 30 2020 | n/a | n/a | ₹2b |
| Jun 30 2020 | n/a | n/a | ₹1b |
| Mar 31 2020 | ₹10m | ₹10m | ₹1b |
| Dec 31 2019 | n/a | n/a | ₹879m |
| Sep 30 2019 | n/a | n/a | ₹834m |
| Jun 30 2019 | n/a | n/a | ₹780m |
| Mar 31 2019 | ₹10m | ₹10m | ₹804m |
| Dec 31 2018 | n/a | n/a | ₹666m |
| Sep 30 2018 | n/a | n/a | ₹582m |
| Jun 30 2018 | n/a | n/a | ₹463m |
| Mar 31 2018 | ₹12m | ₹10m | ₹358m |
Rémunération vs marché: Mark's total compensation ($USD621.97K) is above average for companies of similar size in the Indian market ($USD384.17K).
Rémunération et revenus: Mark's compensation has increased by more than 20% in the past year.
PDG
Mark Saldanha (52 yo)
8.8yrs
Titularisation
₹52,161,600
Compensation
Mr. Mark B. Saldanha, M.Sc. (Maths) & (Stat.)., Dip. (Fin. Mgt.) serves as Promoter and Managing Director of Marksans Pharma Limited, which he joined in October 6, 2005 (alternate name, Glenmark Laboratori...
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Non-Independent Executive Chairman & MD | 8.8yrs | ₹52.16m | 43.8% ₹ 43.7b | |
| Whole-time Director | 9.9yrs | ₹7.03m | 0.073% ₹ 72.7m | |
| Whole-time Director | 5.6yrs | ₹15.25m | pas de données | |
| Non-Executive Director & Non-Independent | 3yrs | pas de données | pas de données | |
| Non-Executive & Independent Director | 5.1yrs | ₹40.00k | pas de données | |
| Independent Director | 1.3yrs | pas de données | pas de données | |
| Non-Executive & Independent Director | 12.8yrs | ₹40.00k | pas de données | |
| Non-Executive Independent Director | 6.4yrs | ₹200.00k | pas de données |
6.0yrs
Durée moyenne de l'emploi
53.5yo
Âge moyen
Conseil d'administration expérimenté: MARKSANS's board of directors are considered experienced (6 years average tenure).